MASLD, MAFLD, or NAFLD criteria: have we re-created the confusion and acrimony surrounding Metabolic syndrome?

Byrne, Christopher D. and Targher, Giovanni (2024) MASLD, MAFLD, or NAFLD criteria: have we re-created the confusion and acrimony surrounding Metabolic syndrome? Metabolism and Target Organ Damage. (In Press)

Record type: Article

Abstract

In 1980, there was the first description of patients with nonalcoholic steatohepatitis (NASH), most of whom were overweight and had type 2 diabetes. In the following years, there has been a growing appreciation that metabolic dysfunction underpins this liver disease, and metabolic dysfunction also contributes to the increased risk of extrahepatic complications, manifest in nonalcoholic fatty liver disease (NAFLD) as a multisystem disease. In 2020 & 2023, it was proposed that NAFLD should be renamed and reclassified as metabolic dysfunction-associated fatty liver disease (MAFLD) or metabolic dysfunction-associated steatotic liver disease (MASLD), respectively. Despite subtle differences between MAFLD or MASLD, there is excellent congruence between NAFLD, MAFLD or MASLD definitions, and affected patients usually meet criteria for all. The following is a perspective of the authors’ views as to the challenges and advantages of the new fatty liver disease terminology and classification.

Text

Revision-MTOD-2024-6-Manuscript-File.v3_cb - Accepted Manuscript

Restricted to Repository staff only until 19 February 2026.

Available under License University of Southampton Accepted Manuscript Licence.

Request a copy